Full Year 2025 Inventiva SA Earnings Call Transcript
Key Points
- Inventiva SA (IVA) completed enrollment for its global Phase III clinical trial, NATIV-3, marking a significant operational milestone.
- The company is well-funded, with EUR230.9 million in cash equivalents and short-term deposits, ensuring financial stability beyond the anticipated NATIV-3 readout.
- Inventiva SA (IVA) strategically sold global rights to OdaParcel, potentially receiving up to $90 million in milestone payments and royalties, allowing focus on lanifibranor.
- Lanifibranor has received both breakthrough therapy and fast-track designations from the FDA, highlighting its potential as a treatment for MASH.
- The leadership team has been strengthened with key appointments to align with the company's strategic focus on lanifibranor and MASH.
- The top-line readout for the NATIV-3 trial has been delayed to Q4 2026, which may impact investor expectations.
- Despite improvements, only around 10% of the estimated 18 million people in the US with MASH have been diagnosed, indicating a significant gap in market penetration.
- The company faces competition from Madrigal, which has seen strong market uptake in the US, posing a challenge for lanifibranor's market entry.
- There are concerns about weight gain associated with lanifibranor, which could affect its tolerability and acceptance among patients.
- The company is reliant on the success of the NATIV-3 trial for future funding, as the third tranche of financing is contingent on positive trial results.
Good morning. Good afternoon, everyone, and thank you for joining Inventiva's full year 2025 financial results and business update.
Our press release was issued yesterday evening, and this webcast and slides will be available in the Investor section on our website following the call.
Joining us on the call today are Andrew Obenshain, Chief Executive Officer, Jean Volotier, Chief Financial Officer and Dr. Jason Campagna, Chief Medical Officer and President of R&D.
I would like to remind everyone that statements made during today's conference call and during the Q&A session may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Please refer to slide 2 of the slides and our SEC and AMF filings for a discussion of associated risks. These statements reflect our views as of today and should not be relied upon as representing our views at any later date.
With that, I will now turn it over to Andrew, starting on slide 3. Andrew.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
